PSA

As a committed ally, White Ribbon releases Short Life Stories addressing violence against the transgender communities

Retrieved on: 
Monday, November 13, 2023

TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- White Ribbon launches its newest campaign, Short Life Stories which follows the life of a transgender woman from her transition onward.

Key Points: 
  • TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- White Ribbon launches its newest campaign, Short Life Stories which follows the life of a transgender woman from her transition onward.
  • The public service announcement (PSA) is a call-to-action in response to the rising hate, discrimination, and violence against the transgender communities.
  • “As a dedicated ally, White Ribbon has developed Short Life Stories to honour the transgender communities and highlight the profound reality that the journey towards their authentic selves can be a long and emotional process.
  • To book an interview with any of our following spokespeople or for more information about Short Life Stories, please contact:

Nonprofit Sector Faces Pressing Challenges in Worker Stress, Public Trust, and Donor Participation, Shows New Report at the 2023 Upswell Summit

Retrieved on: 
Monday, November 13, 2023

Independent Sector launched the report in advance of the 2023 Upswell Summit , co-hosted with Social Venture Partners (SVP) Dallas in Dallas, Texas on November 15-17, 2023.

Key Points: 
  • Independent Sector launched the report in advance of the 2023 Upswell Summit , co-hosted with Social Venture Partners (SVP) Dallas in Dallas, Texas on November 15-17, 2023.
  • The 2023 Upswell Summit will provide a central meeting place for more than 600 nonprofit and foundation leaders, philanthropists, business and corporate leaders, activists, academics, journalists, and changemakers.
  • The report covers sector health data, as well as Independent Sector’s analysis from 2022 through the second quarter of 2023.
  • View the official PSA for the 2023 Upswell Summit here: https://youtu.be/sKKuyP41vDI
    You may also follow along on social media using #Upswell2023.

Internationally Recognized Urologist, Robotic Surgeon and Researcher Dr. Andrew J. Stephenson Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Monday, December 18, 2023

is pleased to announce that Andrew J. Stephenson, MD, MBA, FACS, FRCS(C) has joined its care team .

Key Points: 
  • is pleased to announce that Andrew J. Stephenson, MD, MBA, FACS, FRCS(C) has joined its care team .
  • Dr. Stephenson has performed more than 2,000 robotic urology surgeries in his career.
  • Associated Medical Professionals of NY is a leading multi-specialty practice spanning 19 locations in Central New York, including ten offices and nine hospitals.
  • Christopher M. Pieczonka, MD, Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners , stated, “A.M.P.

Join Kantata at the Salesforce World Tour New York City on 12/14

Retrieved on: 
Tuesday, December 12, 2023

Kantata , the leading global supplier of purpose-built technology for professional services, will showcase its Professional Services Cloud at the Salesforce World Tour New York City — a free event taking place December 14, 2023, 9:00 am – 5:00 pm ET at the Jacob Javits Center.

Key Points: 
  • Kantata , the leading global supplier of purpose-built technology for professional services, will showcase its Professional Services Cloud at the Salesforce World Tour New York City — a free event taking place December 14, 2023, 9:00 am – 5:00 pm ET at the Jacob Javits Center.
  • “Kantata fills the gaps traditional PSA solutions ignore,” said Sarah Edwards, Chief Product Officer at Kantata.
  • Kantata’s demo experts will showcase the Kantata Professional Services Cloud on the expo floor in the World Tour Campground at booth #207.
  • Don't miss out – catch the live showcase on Salesforce+ and explore the transformative capabilities from the convenience of your digital space.

Veteran Brings Lawsuit Against U.S. Government and Cerner After Defective Veterans Affairs Electronic Health Record (EHR) System Irreparably Delays Cancer Diagnosis, According to Luvera Law Firm

Retrieved on: 
Tuesday, December 5, 2023

In that time, say Bourg’s doctors, the cancer spread to other parts of his body and is now terminal.

Key Points: 
  • In that time, say Bourg’s doctors, the cancer spread to other parts of his body and is now terminal.
  • “What happened to Charlie is not only tragic – it’s inexcusable,” said Mark Kamitomo of Luvera Law Firm, one of the attorneys representing Bourg.
  • “Electronic health records are intended to make care efficient and accurate, passing information seamlessly between providers to give the best care.
  • In this case, Charlie would have been better served if his doctor had sent the referral by handwritten letter.

Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval

Retrieved on: 
Monday, December 4, 2023

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (“PSA”) which provides for the Company to acquire a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection,” for $60,000,000.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (“PSA”) which provides for the Company to acquire a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection,” for $60,000,000.
  • The PSA was previously disclosed by the Company in a Form 8-K filing, dated November 27, 2023.
  • Robert Mattacchione, Novo’s CEO and Chairman of the Board, stated, “The magnitude of the world-famous Ophir Collection is expected to optimize the company’s monetization opportunity resulting in a significant cash surplus position while providing the company with both debt retirement and growth initiative solutions.
  • Securing the financing required for the execution of this transaction has been a significant undertaking and we look forward to calling the collection ours.”

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Retrieved on: 
Friday, December 1, 2023

Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.

Key Points: 
  • Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.
  • “We developed the Decipher Prostate Genomic Classifier to provide actionable information that helps guide patient care,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • “The data presented at SUO 2023 show how users of our test, conducting prospective research on their own patients, affirm the utility of Decipher in real-world settings.
  • We are very grateful for the work conducted by these clinician-scientists on behalf of the entire prostate cancer research community.”

Blue Earth Diagnostics Announces Publication of Post-hoc Analysis Evaluating Impact of Urinary Activity on Image Interpretation of POSLUMA® (Flotufolastat F 18) PET in Prostate Cancer

Retrieved on: 
Tuesday, November 28, 2023

The analysis was based on data from Blue Earth Diagnostics’ prospective Phase 3 LIGHTHOUSE1 and SPOTLIGHT2 studies that evaluated the diagnostic performance and safety of POSLUMA in newly diagnosed and recurrent prostate cancer.

Key Points: 
  • The analysis was based on data from Blue Earth Diagnostics’ prospective Phase 3 LIGHTHOUSE1 and SPOTLIGHT2 studies that evaluated the diagnostic performance and safety of POSLUMA in newly diagnosed and recurrent prostate cancer.
  • Halo artifacts, which can inhibit image assessment, were very rare, and were absent in 99.7% (710/712) of patients by majority read.
  • Ureteric activity, which can also limit assessment of lymph nodes distant to the bladder, was also absent in a majority of patients (56%, 401/712).
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Retrieved on: 
Wednesday, November 22, 2023

Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.
  • Collectively, the posters will report data from more than 60,000 patients.
  • The American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year.
  • An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention.

Certinia, a Leader in Professional Services Automation, Selects Ooma Enterprise for Call Centers Across the Globe

Retrieved on: 
Tuesday, November 14, 2023

Ooma, Inc ., a smart communications platform for businesses and consumers, today announced that Certinia, a leader in Professional Services Automation, has selected Ooma Enterprise to power its inbound and outbound call centers across the globe.

Key Points: 
  • Ooma, Inc ., a smart communications platform for businesses and consumers, today announced that Certinia, a leader in Professional Services Automation, has selected Ooma Enterprise to power its inbound and outbound call centers across the globe.
  • Employees at Certinia locations in Australia, the Netherlands, Spain, the United Kingdom and the United States were able to migrate to a single unified solution – Ooma Enterprise.
  • The introduction of Ooma Enterprise was so successful that Certinia has since extended the service to its inbound sales and customer support teams.
  • “We’re also appreciative that Certinia recognized how Ooma Enterprise can expand within their organization to provide more value than initially expected.”